Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
V Silvestri et al, JAMA Oncology, July 2, 2020
V Silvestri et al, JAMA Oncology, July 2, 2020
In this cohort study of 6902 men with a BRCA1 or BRCA2 pathogenic variant, being affected by cancer, particularly breast, prostate, and pancreatic cancers and developing multiple primary tumors, was associated with a higher probability for a man of being a BRCA2, rather than a BRCA1, pathogenic variant carrier.
No hay comentarios:
Publicar un comentario